Management of psoriasiform lesions in IBD patients under anti-TNF agents includes topical therapy and if possible, anti-TNF temporary suspension or withdrawal, or switching with ustekinumab (Figure 10). The gene discussed is TNF; the disease is inflammatory bowel disease.